306 per cent return: Net profit rallies over 59 per cent; Multibagger ship-building stock hits fresh 52-week high!
306 per cent return: Net profit rallies over 59 per cent; Multibagger ship-building stock hits fresh 52-week high!
FII’s have increased their holdings from 2.68 per cent to 3.11 per cent in the quarter ending June 2023.
The President of India holds a substantial stake of 74.50 per cent.
Ashish Kacholia's pick: Small-cap reports stellar Q1 results; Net profit rises 13 per cent to Rs 17 crore!
It's worth noting that prominent investor Ashish Kacholia holds a 2.13 per cent stake in the company.
Pharma Intermediates took the lead, contributing 84.0 per cent, followed by Specialty Chemicals at 16.0 per cent.
65 per cent dividend: Stellar Q1 results net profit skyrockets 326 per cent to Rs 601 crore; Stock hits 52-week high mark!
During this timeframe, this auto component stock has successfully completed seven acquisitions.
The stock has witnessed significant buying activity surging more than 70 per cent in the last 1 year.
626 per cent return: Multibagger ship building PSU reports stellar Q1 performance; do you own it?
The President of India holds 84.83 per cent stake in the company.
The stock has witnessed significant buying activity surging more than 626 per cent in the last 3 years.
Miniratna reports strong Q1 performance: Net profit skyrockets 2-fold; Do you own it?
The stock has witnessed significant buying activity surging more than 93 per cent in the last 1 year.
Additionally, the EPS for the quarter amounted to Rs 8.32 per share, indicating a positive impact on shareholders' earnings.
233 per cent return: FII's favourite reports stellar Q1 performance; hits 10 per cent upper circuit!
The company achieved an impressive 53.24 per cent growth in its top line, reaching Rs 1,488 crore.
In summary, these outcomes indicate robust growth in both revenue and profitability for the company during the initial quarter of FY24.
Axis Bank's bold move and Stellar Q1 Performance Ignites 11 per cent intraday surge: But a twist awaits!
The revenue jumped 180.19 per cent, reaching Rs 9,168 crore compared to the same quarter of the previous year.
The stock has witnessed significant buying activity as it has surged more than 65 per cent in the last 3 years.
Dolly Khanna, Vijay Kedia’s pick zooms 21 per cent in just 2 days: Q1FY24 and stock split sparks heavy buying!
The stock has witnessed significant buying activity as it has given multibagger returns of more than 900 per cent in just 3 years.
The bottom line experienced a upswing of 17 per cent, reaching Rs 17 crore in Q1 FY24, compared to previous quarter.
Mukul Agarwal’s recent multibagger pick: Net profit jumps multi-folds to Rs 47 crore; stock hits upper circuit!
The stock has witnessed significant buying activity surging more than 902 per cent in the last 3 years.
As of June 30, 2023, the company's total order book stood at Rs 542.84 Crore, comprising two main segments: AMC and Equipment.
Stellar Q1 performance: Net profit rockets 97 per cent to Rs 2,774 Crore; revenue zooms 23 per cent YoY!
The stock has witnessed significant buying activity surging more than 152 per cent in the last 3 years.
In the quarter ending June 2023, Mahindra & Mahindra Limited net profit stood at Rs 2,773.73 crore, marking a significant surge of 97.6 per cent compared to Rs 1,403.61 crore recorded in the corresponding quarter of the previous year.
Hot stock: This Godrej group stock reports stellar Q1FY24 results; know more here!
The stock has witnessed significant buying activity as it has surged more than 65 per cent in the last 3 years.
Over the past five years, the company has achieved an impressive CAGR of 90.1 per cent in terms of profit growth.
Stellar performance: Q1FY24 net profit skyrockets by 100 per cent; pharma stock hits back-to-back 52-week high!
The stock has experienced significant buying activity, soaring by over 70 per cent in the past 1 year.
Overall, Trident Lifeline Limited's Q1FY24 financial performance demonstrates its strong market position and ability to capitalize on growth opportunities in the pharmaceutical industry.